Re: New drug on the horizon

[Guest guest]

At 07:39 AM 6/28/05 -0400, you wrote:

>This drug Ceflatonin is actually homoharringtonine or HHT. I was wondering

>if any of the list members going to MD have come across this trial

>drug or if we know anyone who is in the trial. From what I understand HHT

>goes after a number of pathways including regulating apoptosis and

>angiogenesis. This might be interesting since we all know it will take a

>combination of drugs to " cure " CML.

>

>Happy reading!

>Cheers,

>Cheryl-Anne

Hi Cheryl-Anne,

I responded to this article on Jerry's list....to me this sounds like

drug company hype....the type of thing written for stockholders.

A number of us (myself, Jerry Mayfield and others I know) were on triple

therapy in the old days...inf, ara-c and HHT (via catheter at that time...I

think it is in pill form now)........and the results of this combo were

nothing spectacular. This was in 1999 at MDACC. Also, I know at least one

person who did Gleevec and HHT at Hammersmith in the UK recently....and I

believe stopped because of bad side effects.

So this is not really a new drug, and I don't remember anyone thinking it

was really impressive.

C.

[Guest guest]

Hi ,

Thanks for sharing your experience with HHT. I remember hearing from

a few others about their treatment with HHT.

While this is information for share holders (and no, I am not a share

holder ;>) this is interesting when we think of the fact that there

are about 60,000 cmlers in the world and not all us are being treated

with IM or BMS. Just recently I did a little market research and if

you take into consideration that of all the list servs that I know of

we are about 2,000 (taking into consideration that there are many of

us signed up on multiple lists)cmlers on the internet which is a

small fraction of the total population of CMLers. When I come across

articles like this it reminds me that we haven't heard from anyone on

this trial, yet it has managed to make it to phase II. The other

point is that while patients are on this trial they are unavailable

for the other trials of BMS or AMN107. Additionally I was curious if

any of the patients in this phase II trial are doing this because

they couldn't get into the BMS trial.

I can't figure out why the article headline calls it a new drug

either, maybe because it is in pill form - who knows. But if anyone

is going to MDACC in the near future, maybe they can inquire about

this trial.

Cheers to all,

Cheryl-Anne

>

> Hi Cheryl-Anne,

>

> I responded to this article on Jerry's list....to me this sounds

like

> drug company hype....the type of thing written for stockholders.

>

> A number of us (myself, Jerry Mayfield and others I know) were on

triple

> therapy in the old days...inf, ara-c and HHT (via catheter at that

time...I

> think it is in pill form now)........and the results of this combo

were

> nothing spectacular. This was in 1999 at MDACC. Also, I know at

least one

> person who did Gleevec and HHT at Hammersmith in the UK

recently....and I

> believe stopped because of bad side effects.

>

> So this is not really a new drug, and I don't remember anyone

thinking it

> was really impressive.

>

> C.

>

>